UNCY FY2024 EPS Boosted by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at Brookline Capital Management boosted their FY2024 earnings per share estimates for shares of Unicycive Therapeutics in a research note issued to investors on Wednesday, November 13th. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings per share of ($0.03) for the year, up from their prior estimate of ($0.08). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ Q4 2024 earnings at ($0.07) EPS and FY2025 earnings at ($0.15) EPS.

UNCY has been the topic of a number of other reports. Benchmark reissued a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, September 6th. HC Wainwright reissued a “buy” rating and issued a $2.50 price target on shares of Unicycive Therapeutics in a research note on Tuesday, November 12th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $5.13.

Unicycive Therapeutics Stock Performance

Unicycive Therapeutics stock opened at $0.46 on Monday. The stock has a market cap of $47.24 million, a PE ratio of -0.47 and a beta of 2.29. The stock has a 50-day moving average price of $0.43 and a 200 day moving average price of $0.54. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.82.

Institutional Trading of Unicycive Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Unicycive Therapeutics during the 3rd quarter worth approximately $29,000. Walleye Capital LLC purchased a new stake in Unicycive Therapeutics during the 3rd quarter worth approximately $2,040,000. Acuta Capital Partners LLC purchased a new stake in Unicycive Therapeutics during the 3rd quarter worth approximately $807,000. Great Point Partners LLC purchased a new stake in Unicycive Therapeutics during the 3rd quarter worth approximately $3,491,000. Finally, Bleakley Financial Group LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at approximately $33,000. 40.42% of the stock is owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.